Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Alliança Saúde e Participações S.A. (AALR3.SA)
BRL3.09
-0.08 (-2.52%)
BR SAO Healthcare Medical - Diagnostics & Research
Address
Alameda Vicente Pinzon, 51 1830
São Paulo, SP, BR
São Paulo, SP, BR
CEO
Ricardo de Magalhaes Sartim
Website
allianca.com
IPO
2016-10-28
ISIN BRAALRACNOR6
Description
Alliança Saúde e Participações S.A. functions as a holding entity primarily focused on delivering medical diagnostic services. Its comprehensive service portfolio encompasses diagnostic imaging, record-based assessments, nuclear medicine procedures, cytological analysis, anatomical pathology, and a range of clinical laboratory tests. Geraldo Mol Starling Filho established the organization on August 5, 1992, and its central operations are located in Sao Paulo, Brazil.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
BRL3.09
-0.08 (-2.52%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
56.1K
Beta
0.51
Float Shares
18.69M
Free Float %
12.3%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +5.03% | +19.53% | -34.26% | -28.57% | -23.66% | -41.71% | -84.45% | -71.07% | -81.51% | -81.51% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
3.09
DCF (Unlevered)
3.61
+16.8%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
100% Bullish
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 3 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
0.37
Distress
Piotroski F-Score
4 / 9
Average
MOAT Score
2 / 10
No MOAT
Composite Rating
C-
Overall Score
1 / 5
Low
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
4 / 5
High
Operational MOAT
✗ Below peers
-
Revenue growth Medical - Diagnostics & Research: +7.9%+3.2% Q3'25: +3.3% (vs Q3'24)
-
EPS growth Medical - Diagnostics & Research: +30.8%+43.5% ★ Q3'25: +239.9% (vs Q3'24)
-
FCF margin FCF growth · Medical - Diagnostics & Research: +32.2%-23.1% Q3'25: +13.9% (vs Q3'24)
-
EBIT margin Medical - Diagnostics & Research: +9.6%+6.8% Q3'25: +13.3% (vs Q3'24)
-
ROIC Medical - Diagnostics & Research: +5.2%+4.2% Q3'25: +6.2% (vs Q3'24)
-
Share dilution Medical - Diagnostics & Research: 0.0%+0.5% Q3'25: +27.7% (vs Q3'24)
-
Debt / EBITDA Net debt/EBITDA · Medical - Diagnostics & Research: -0.13×5.15× Q3'25: 1.92× (vs Q3'24)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
|---|---|---|---|---|---|---|---|---|---|
| Revenue |
951.47M
est: 942.58M (+0.9%)
|
1.08B
est: 1.09B (-0.9%)
|
1.08B
est: 1.08B (-0.3%)
|
1.07B
est: 1.07B (+0.3%)
|
928.79M
est: 906.90M (+2.4%)
|
1.14B
est: 1.16B (-1.6%)
|
1.09B
est: 1.24B (-12.6%)
|
1.18B
est: 1.30B (-9.5%)
|
1.22B
est: 1.22B (+0.0%)
|
| EBITDA |
156.28M
est: 121.18M (+29.0%)
|
137.08M
est: 139.82M (-2.0%)
|
203.98M
est: 138.86M (+46.9%)
|
245.12M
est: 137.49M (+78.3%)
|
101.67M
est: 116.60M (-12.8%)
|
206.49M
est: 148.49M (+39.1%)
|
74.62M
est: 159.68M (-53.3%)
|
154.73M
est: 167.65M (-7.7%)
|
184.67M
est: 203.78M (-9.4%)
|
| EBIT |
101.92M
est: 22.75M (+348.0%)
|
58.06M
est: 26.25M (+121.2%)
|
121.36M
est: 26.07M (+365.6%)
|
127.25M
est: 25.81M (+393.0%)
|
-17.51M
est: 21.89M (-180.0%)
|
86.78M
est: 27.87M (+211.3%)
|
-43.12M
est: 29.97M (-243.8%)
|
41.37M
est: 31.47M (+31.5%)
|
82.44M
est: 155.86M (-47.1%)
|
| Net Income |
14.79M
est: 24.98M (-40.8%)
|
6.65M
est: 38.06M (-82.5%)
|
40.09M
est: 36.87M (+8.7%)
|
41.30M
est: 44.40M (-7.0%)
|
-97.42M
est: -103.47M (+5.9%)
|
-5.63M
est: 35.68M (-115.8%)
|
-227.81M
est: 27.35M (-932.8%)
|
-227.88M
est: 55.90M (-507.7%)
|
-129.12M
|
| SGA |
257.28M
est: 227.65M (+13.0%)
|
216.14M
est: 262.66M (-17.7%)
|
175.72M
est: 260.86M (-32.6%)
|
159.02M
est: 258.29M (-38.4%)
|
172.16M
est: 219.03M (-21.4%)
|
261.93M
est: 278.95M (-6.1%)
|
338.41M
est: 299.96M (+12.8%)
|
325.08M
est: 314.94M (+3.2%)
|
248.60M
est: 293.92M (-15.4%)
|
| EPS |
0.15
est: 0.21 (-28.6%)
|
0.06
est: 0.32 (-82.2%)
|
0.34
est: 0.31 (+9.7%)
|
0.35
est: 0.37 (-6.2%)
|
-0.82
est: -0.87 (+5.7%)
|
-0.05
est: 0.30 (-115.9%)
|
-1.93
est: 0.23 (-939.1%)
|
-1.93
est: 0.47 (-510.6%)
|
-1.09
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-28 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-27 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-26 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-25 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-22 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-21 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-20 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-19 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-18 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-15 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-14 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-13 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-12 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-11 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-08 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-07 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-06 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-05 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-04 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-30 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-29 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-28 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-27 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-24 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-23 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-22 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-20 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-17 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-16 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-60.44M
OE per share TTM
-0.84
Owner's Yield
-11.27%
Maintenance CapEx ratio
325.61%
Maint CapEx / Avg PPE
67.1%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 1 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Dimensional World ex U.S. Core Equity 2 ETF DFAX | 0.00% | 114.42 | 0.28% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
16.5K
Shares Outstanding
152.32M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Jose Luiz Mendes Ramos Jr. | Chief Legal & Compliance Officer, Investor Relations Officer and Member of Executive Board | — | male |
| Ricardo de Magalhaes Sartim | CEO, CFO & Member of Executive Board | — | — |
| Wilson Costa Ferreira | Director of Controlling and Strategic Cash | — | — |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for AALR3.SA
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
